Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has shared an update.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a change in beneficial ownership of the company’s common stock. On November 3, 2025, Sandercock acquired 2,000 shares through stock options at a price of $101.64 per share and disposed of 3,000 shares at $247.54 per share. This transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned trading strategy. The change in ownership reflects ongoing management of equity holdings by the company’s executive, which may impact investor perceptions and the company’s stock performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of products related to sleep disorders, respiratory care, and connected health solutions. The company is known for its innovative devices and software applications that help improve the quality of life for patients with sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Average Trading Volume: 1,153,851
Technical Sentiment Signal: Buy
Current Market Cap: A$55.65B
For an in-depth examination of RMD stock, go to TipRanks’ Overview page.